Private tuberculosis testing is cheaper in IndiaBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i677 (Published 03 February 2016) Cite this as: BMJ 2016;352:i677
- Cheryl Travasso
A report in Lancet Global Health has criticised the high cost and poor availability of the latest tuberculosis (TB) test in countries with a high burden of the disease, but praised an initiative in India for making WHO approved diagnostics available at concessional prices.1
Researchers looked at the availability and cost of the Xpert MTB/RIF test2 in the private sector in 12 high burden countries: Afghanistan, Bangladesh, Cambodia, India, Indonesia, Kenya, Myanmar, Nigeria, Pakistan, the Philippines, Uganda, and Vietnam.
Xpert MTB/RIF is a rapid automated test that takes less …